{"id":109,"date":"2022-02-03T08:48:01","date_gmt":"2022-02-03T13:48:01","guid":{"rendered":"https:\/\/web.uri.edu\/riid\/?page_id=109"},"modified":"2022-02-25T11:24:27","modified_gmt":"2022-02-25T16:24:27","slug":"outcomes-and-pharmacoepidemiology","status":"publish","type":"page","link":"https:\/\/web.uri.edu\/riid\/research\/outcomes-and-pharmacoepidemiology\/","title":{"rendered":"Outcomes and Pharmacoepidemiology"},"content":{"rendered":"<section class=\"cl-wrapper cl-menu-wrapper\"><nav id=\"\" class=\"cl-menu  \" data-name=\"Main\" data-show-title=\"0\"><ul id=\"menu-main\" class=\"cl-menu-list cl-menu-list-no-js\"><li id=\"menu-item-28\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-28\"><a href=\"https:\/\/web.uri.edu\/riid\/\">Home<\/a><\/li>\n<li id=\"menu-item-283\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-283\"><a href=\"https:\/\/web.uri.edu\/riid\/news-media\/\">News &amp; Media<\/a><\/li>\n<li id=\"menu-item-32\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-32\"><a href=\"https:\/\/web.uri.edu\/riid\/research\/\">Research<\/a><\/li>\n<li id=\"menu-item-29\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-29\"><a target=\"_blank\" href=\"https:\/\/web.uri.edu\/antimicrobial-stewardship\/\">Clinical<\/a><\/li>\n<li id=\"menu-item-31\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-31\"><a target=\"_blank\" href=\"https:\/\/www.researchgate.net\/profile\/Kerry-Laplante\">Publications<\/a><\/li>\n<li id=\"menu-item-33\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-33\"><a href=\"https:\/\/web.uri.edu\/riid\/research-team\/\">Research Team<\/a><\/li>\n<li id=\"menu-item-30\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-30\"><a href=\"https:\/\/web.uri.edu\/riid\/fellowship\/\">Fellowship<\/a><\/li>\n<\/ul><\/nav><\/section>\n\n\n\n<h1 class=\"wp-block-heading\">Outcomes and Pharmacoepidemiology<\/h1>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"alignleft size-medium\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"200\" src=\"https:\/\/web.uri.edu\/wp-content\/uploads\/sites\/2101\/kllab6-300x200.jpg\" alt=\"\" class=\"wp-image-211\" srcset=\"https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-300x200.jpg 300w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-1024x683.jpg 1024w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-768x512.jpg 768w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-1536x1024.jpg 1536w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-364x243.jpg 364w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-500x333.jpg 500w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-1000x667.jpg 1000w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6-1280x853.jpg 1280w, https:\/\/web.uri.edu\/riid\/wp-content\/uploads\/sites\/2101\/kllab6.jpg 1650w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure><\/div>\n\n\n\n<p>The Outcomes Research Division began in 2008 and is directed by Dr. Aisling Caffrey, Ph.D., M.S. This division focuses on real-world evidence in the treatment of drug-resistant and difficult to treat infections. The Outcomes Research Division conducts pharmacoepidemiologic and health outcomes studies on topics ranging from medication utilization, to comparative effectiveness and safety, with expertise in infectious disease treatment heterogeneity. Additionally, this group conducts infectious disease epidemiologic research.<\/p>\n\n\n<a class=\"cl-button   prominent\" href=\"https:\/\/www.researchgate.net\/profile\/Kerry-Laplante\" title=\"\">Research gate publication List<\/a>","protected":false},"excerpt":{"rendered":"<p>Outcomes and Pharmacoepidemiology The Outcomes Research Division began in 2008 and is directed by Dr. Aisling Caffrey, Ph.D., M.S. This division focuses on real-world evidence in the treatment of drug-resistant and difficult to treat infections. The Outcomes Research Division conducts pharmacoepidemiologic and health outcomes studies on topics ranging from medication utilization, to comparative effectiveness and [&hellip;]<\/p>\n","protected":false},"author":639,"featured_media":0,"parent":14,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-109","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/pages\/109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/users\/639"}],"replies":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/comments?post=109"}],"version-history":[{"count":5,"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/pages\/109\/revisions"}],"predecessor-version":[{"id":248,"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/pages\/109\/revisions\/248"}],"up":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/pages\/14"}],"wp:attachment":[{"href":"https:\/\/web.uri.edu\/riid\/wp-json\/wp\/v2\/media?parent=109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}